<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methadone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methadone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methadone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9623" href="/d/html/9623.html" rel="external">see "Methadone: Drug information"</a> and <a class="drug drug_patient" data-topicid="10849" href="/d/html/10849.html" rel="external">see "Methadone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58073961"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Requiring Updates to Opioid Prescribing Information</span>
<span class="collapsible-date">April 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has issued a drug safety communication to announce safety-related updates to the prescribing information for immediate-release (IR) and extended-release (ER)/long-acting (LA) opioid analgesics, including updates to Boxed Warnings, Indications and Usage, Dosage and Administration, Warnings and Precautions, and the Medication Guide. These safety labeling changes are intended to provide clarity on appropriate patient populations for opioid treatment, appropriate dosage and administration, and updated information on the risks associated with opioid use. The required safety labeling changes include stating:</p>
<ul>
<li>
<p style="text-indent:0em;">the risk of overdose increases as the dosage increases for all opioid pain medicines;</p></li>
<li>
<p style="text-indent:0em;">IR opioids should not be used for an extended period of time unless a patient's pain remains severe enough to require them and alternative treatment options continue to be inadequate;</p></li>
<li>
<p style="text-indent:0em;">many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine;</p></li>
<li>
<p style="text-indent:0em;">it is recommended to reserve ER/LA opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate; and</p></li>
<li>
<p style="text-indent:0em;">a warning about opioid-induced hyperalgesia (OIH), including information on differentiating OIH symptoms from those of opioid tolerance and withdrawal.</p></li></ul>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use&amp;token=W5X7myh%2Fi%2FQGr76L%2FoSZbu%2BwYKvRHJDB8O4e79tNg%2FJelrlNqz4gv2DJCwSZVkI3gE10g96a4t1z3Z59rSO%2Fb6izsjmacse6U4o7Ho29jYziQVHf0MYzW7j8%2B8LrQ2%2B4Ru4vvCtWrdS3FrWL%2B0kz4ajIBlnws%2B6VB3AxZWaliq8%3D&amp;TOPIC_ID=12590" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5709037"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Addiction, abuse, and misuse (injection, immediate release tablet, oral solution [1 mg/mL and 2 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because the use of methadone exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Misuse, abuse, and diversion of opioids (dispersible tablet, oral concentrate [10 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dispersible tablets and oral concentrate contain methadone, an opioid agonist and schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid analgesic risk evaluation and mitigation strategy (REMS) (immediate release tablet, oral solution [1 mg/mL and 2 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Health care providers are strongly encouraged to complete a REMS-compliant education program and counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Life-threatening respiratory depression (injection, immediate release tablet, oral solution [1 mg/mL and 2 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, or fatal respiratory depression may occur with use of methadone, especially during initiation or following a dose increase. To reduce the risk of respiratory depression, proper dosing and titration of methadone are essential.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Life-threatening respiratory depression (dispersible tablet, oral concentrate [10 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Respiratory depression, including fatal cases, has been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused. Proper dosing and titration are essential, and methadone should only be prescribed by health care professionals who are knowledgeable in the use of methadone for detoxification and maintenance treatment of opioid addiction. Monitor for respiratory depression, especially during initiation of methadone or following a dose increase. The peak respiratory depressant effect of methadone occurs later, and persists longer than the peak pharmacologic effect, especially during the initial dosing period.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Life-threatening QT prolongation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">QT interval prolongation and serious arrhythmia (torsades de pointes) have occurred during treatment with methadone. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Closely monitor patients with risk factors for development of prolonged QT interval, a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction for changes in cardiac rhythm during initiation and titration of methadone.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Accidental ingestion (oral formulations):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Accidental ingestion of even one dose of methadone, especially by children, can result in a fatal overdose of methadone.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neonatal opioid withdrawal syndrome (injection, immediate release tablet, oral solution [1 mg/mL and 2 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Conditions for distribution and use of methadone products for the treatment of opioid addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">For detoxification and maintenance of opioid dependence, methadone should be administered in accordance with the treatment standards cited in 42 CFR Section 8, including limitations on unsupervised administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Interactions with drugs affecting cytochrome P450 isoenzymes:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The concomitant use of methadone with all cytochrome P450 3A4, 2B6, 2C19, 2C9, or 2D6 inhibitors may result in an increase in methadone plasma concentrations, which could cause potentially fatal respiratory depression. In addition, discontinuation of concomitantly used CYP450 3A4, 2B6, 2C19, or 2C9 inducers may also result in an increase in methadone plasma concentration. Follow patients closely for respiratory depression and sedation, and consider dosage reduction with any changes of concomitant medications that can result in an increase in methadone levels.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with benzodiazepines or other CNS depressants (injection, immediate release tablet, oral solution [1 mg/mL and 2 mg/mL]):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of methadone and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with benzodiazepines or other CNS depressants (dispersible tablet, oral concentrate [10 mg/mL]:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with benzodiazepines or other CNS depressants, including alcohol, is a risk factor for respiratory depression and death. Reserve concomitant prescribing of benzodiazepines or other CNS depressants in patients in methadone treatment to those for whom alternatives to benzodiazepines or other CNS depressants are inadequate. Follow patients for signs and symptoms of respiratory depression and sedation. If the patient is visibly sedated, evaluate the cause of sedation and consider delaying or omitting daily methadone dosing.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of medication errors (1 mg/mL and 2 mg/mL oral solution)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ensure accuracy when prescribing, dispensing, and administering methadone oral solution. Dosing errors due to confusion between mg and mL, and other methadone oral solutions of different concentrations can result in accidental overdose and death.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F193997"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Methadone HCl Intensol;</li>
<li>Methadose;</li>
<li>Methadose Sugar-Free</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867493"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP Methadone;</li>
<li>Metadol;</li>
<li>Metadol-D;</li>
<li>Methadose;</li>
<li>ODAN-Methadone;</li>
<li>ODAN-Methadone Dye Free</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1053862"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Opioid</span></li></ul></div>
<div class="block don drugH1Div" id="F53462503"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54fef102-e507-4e45-868f-148e3b15088e">Neonatal opioid withdrawal syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neonatal opioid withdrawal syndrome:</b> Limited data available; dosing regimen may vary. <b>Note: </b>In most studies, Finnegan Neonatal Abstinence Scoring tool was utilized to assess severity of withdrawal symptoms; methadone treatment was initiated if 3 consecutive scores were ≥8 or 2 consecutive scores ≥12; doses were increased using these same criteria; in addition to scores ≥8, one study also increased dose if multiple breakthrough doses were required. Other scoring tools (eg, Eat, Sleep, Console [ESC]) have also been used.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose and dose escalation for symptom control</i>: Preterm and term neonates: Oral: Initial: 0.05 to 0.1 mg/kg/dose every 6 hours <b>or </b>0.05 to 0.1 mg/kg/dose every 4 hours; if withdrawal is not controlled, may increase the dose by 0.05 mg/kg/dose; frequency of dose increases varied; see individual studies for weaning details or refer to institutional protocols (AAP [Hudak 2012]; Brown 2015; Hall 2015; Hall 2016; Lai 2017; Lainwala 2005; Wiles 2014; Wiles 2015); one pharmacokinetic study in preterm neonates allowed initial loading doses up to 0.2 mg/kg/dose every 6 hours for 4 doses, followed by rapid weaning over 4 days (van Donge 2019). Other studies have reported on a variety of approaches including using the Finnegan score to determine the initial methadone dose and the use of a symptom triggered methadone protocol utilizing the Eat, Sleep, Console (ESC) assessment tool (Davis 2018; Wachman 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weaning dose after symptoms controlled:</i>
<b>Note: </b>Dose and taper schedule should be individualized based on patient response; monitor closely for withdrawal symptoms as well as signs of accumulation. Weaning of methadone usually occurs after withdrawal symptoms are controlled; typically weaning begins after 24 to 72 hours of stable withdrawal scores (AAP [Hudak 2012]; Hall 2015; Lainwala 2005; Wiles 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: Oral: A standard approach to weaning does not exist; weans are highly variable and patient specific: Decreasing dose by 10% to 20% of the maximum dose every 24 to 48 hours as tolerated is one weaning approach that has been reported; weaning dose and/or frequency daily has also been reported; see individual studies for weaning details or refer to institutional protocols (AAP [Hudak 2012]; Hall 2015; Hall 2016; Lai 2017; Lainwala 2005; van Donge 2019; Wiles 2015).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9539c539-bd90-428f-8595-241220bba4c5">Iatrogenic opioid dependency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iatrogenic opioid dependency:</b> Limited data available, optimal regimen not established. Methadone dose and taper schedule must be individualized and will depend upon patient's previous opioid dose, length of time on opioids, and severity of opioid withdrawal. Use of Withdrawal Assessment Tool (WAT-1) and Sophia Observation Withdrawal Symptom Scale (SOS) have been recommended to monitor for iatrogenic withdrawal symptoms (Franck 2012; Isaac 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i> Neonates: Oral: No standard regimen exists; published regimens vary in conversion factors, when to convert to oral, and how long the taper should be, none of which have been proven to be superior to another; follow institutional protocols as appropriate. Neonates receiving opioids for &gt;96 hours are more likely to experience opioid withdrawal and usually require opioid doses to be weaned and may require transition to methadone. Once methadone dose is stabilized, a weaning schedule of ~10% to 20% reduction of the maximum dose every 24 to 48 hours has been recommended (AAP [Hudak 2012]; Dominguez 2003; Isaac 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Neonates: Oral: Initial: 0.05 to 0.1 mg/kg/dose every 6 hours; increase by 0.05 mg/kg/dose until withdrawal symptoms are controlled; after 24 to 48 hours, the dosing interval can be lengthened to every 12 to 24 hours; to taper dose, wean as tolerated until a dose of 0.05 mg/kg/day, then discontinue (AAP [Hudak 2012]; Anand 1994).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812531"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9539c539-bd90-428f-8595-241220bba4c5">Iatrogenic opioid dependency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iatrogenic opioid dependency:</b> Limited data available, optimal regimen not defined. Methadone dose and taper schedule <b>must be individualized</b> and will depend upon patient's previous opioid dose, length of time on opioids, and severity of opioid withdrawal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i> Children and Adolescents: Several reports have been published, varying in conversion equivalence factors, when to convert to oral, and how long the taper should be, none of which have been proven to be superior to another; follow institutional protocols as appropriate. Patients receiving opioids for &gt;14 days are more likely to experience opioid withdrawal and usually require opioid doses to be weaned, which may require transition to methadone. Once methadone dose is stabilized, a weaning schedule of ~10% to 20% reduction of the original dose every 24 to 48 hours has been recommended (AAP [Galinkin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment</i>: Infants and Children: Oral: Initial: 0.05 to 0.1 mg/kg/dose every 6 hours; increase by 0.05 mg/kg/dose until withdrawal symptoms are controlled; after 24 to 48 hours, the dosing interval can be lengthened to every 12 to 24 hours; to taper dose, wean as tolerated until a dose of 0.05 mg/kg<b>/day</b>, then discontinue (Anand 1994)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e3a9653-67a4-4399-ba72-2fdd9f37aa38">Pain; chronic, severe or palliative care</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain; chronic, severe or palliative care: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Methadone is not generally used for management of acute pain. Doses should be titrated to effect; use lower doses in opioid-naive patients. Management of breakthrough pain should be addressed with another opioid (short-acting). Methadone has high interpatient variability in absorption, metabolism, and relative analgesic potency and exposure accumulates with repeated dosing, resulting in increased methadone potency. Therefore, equianalgesic conversion ratios between methadone and other opioids are not accurate when applied to individuals and will vary depending on baseline opioid requirements. <b>Methadone may accumulate due to its long half-life</b>; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV (preferred), SUBQ: Initial: 0.05 to 0.1 mg/kg/dose every 6 to 24 hours; maximum initial dose: 5 mg/dose; adjust dose and/or interval based on clinical response no more frequently than every 72 hours (Sadhasivam 2021; SCCM [Smith 2022]; Van Cleave 2016; Zeltzer 2020; Zernikow 2009). <b>Note:</b> When used in the palliative care setting, some patients may require higher initial doses based on current opioid dosing for pain (Madden 2019b; Mott 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Initial: 0.05 to 0.2 mg/kg/dose every 6 to 24 hours; maximum initial dose: 5 mg/dose; adjust dose and/or interval based on clinical response no more frequently than every 72 hours (Madden 2017; Madden 2019a; SCCM [Smith 2022]; Ullrich 2020; Van Cleave 2016; Zeltzer 2020). <b>Note:</b> When used in the palliative care setting, some patients may require higher initial doses based on current opioid dosing for pain (Madden 2019b; Mott 2018).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729768"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; initiate at lower doses and titrate slowly; monitor closely for respiratory and CNS depression.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Specific pediatric data is lacking; the following dosage adjustments have been recommended: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Based on pharmacokinetic data and experience with adult patients in renal failure, most suggest no adjustment necessary (Dean 2004; Golightly 2013); however, in patients receiving doses every 4 hours, an increased dosing interval (eg, every 6 to 8 hours) should be considered (Aronoff 2007)</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Based on pharmacokinetic data and experience with adult patients in renal failure, most suggest no adjustment necessary (Dean 2004; Golightly 2013); however, in patients receiving doses every 4 or 6 hours, an increased dosing interval (eg, every 8 to 12 hours) should be considered (Aronoff 2007)</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Reduce dosing interval; administration every 12 to 24 hours has been suggested (Aronoff 2007)</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: Does not increase the elimination of methadone; reduce dosing interval; administration every 12 to 24 hours has been suggested (Aronoff 2007)</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): Does not increase the elimination of methadone; reduce dosing interval; administration every 12 to 24 hours has been suggested (Aronoff 2007)</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Administer every 8 to 12 hours, titrate to effect; after 4 to 5 doses extend the interval to every 8 to 24 hours (Aronoff 2007)</p></div>
<div class="block dohp drugH1Div" id="F52729769"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, methadone undergoes hepatic metabolism and systemic exposure may be increased after repeated dosing. Initiate at lower doses and titrate slowly; monitor closely for respiratory and CNS depression.</p></div>
<div class="block doa drugH1Div" id="F194001"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9623" href="/d/html/9623.html" rel="external">see "Methadone: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Due to high interpatient variability in methadone’s relative analgesic potency and increased potency following repeated methadone dosing, equianalgesic conversion ratios between methadone and other opioids are not accurate when applied to individuals and will vary depending on baseline opioid requirements. Deaths have occurred during conversion from chronic high-dose treatment with other opioids and in patients with a history of opioid use disorder. Special attention is required during treatment initiation, during conversion from one opioid to another, and during dose titration. Consider prescribing naloxone for patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, patients with sleep-disordered breathing, higher opioid dosages (≥50 morphine milligram equivalents [MME]/day orally), and/or concomitant benzodiazepine use (CDC [Dowell 2022], Chou 2016). Methadone has a narrow therapeutic index, especially when combined with other drugs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize dosing regimen based on patient-specific factors (eg, comorbidities, severity of pain, degree of opioid experience/tolerance) and titrate to patient-specific treatment goals. Steady-state plasma concentrations and full analgesic effects are not attained until at least 3 to 5 days on a dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b5d1200e-4b77-4063-a068-a6af2d58ce5e">Chronic pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic pain:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>When used for managing moderate to severe pain, opioids may be part of a comprehensive, multimodal, patient-specific treatment plan for pain. Maximize nonopioid analgesia, if appropriate, prior to initiation of opioid analgesia (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Opioid-naive patients: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 2.5 to 5 mg every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM, IV, SUBQ:</b>
<b>Note:</b> For use only in patients unable to take oral medication (such as during hospitalization). 2.5 to 10 mg every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Titration and maintenance:</b> May increase dose by 2.5 mg per dose no more often than every 5 to 7 days (gradual titration) or by 2.5 to 5 mg per dose every 3 days (faster titration in monitored setting). Once a stable dose is reached, the dosing interval may be extended to every 8 to 12 hours or longer (VA/DoD 2022). Because of high interpatient variability, substantially longer periods between dose increases may be necessary in some patients (up to 12 days). If unacceptable adverse reactions are observed, reduce dose and/or dosing interval (ie, every 8 to 12 hours). Breakthrough pain may require a dose increase or rescue medication with an IR analgesic. Some guidelines note that dose increases should not be &gt;10 mg per day every 5 to 7 days (Chou 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Opioid-tolerant patients:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion from oral morphine to oral methadone:</i> 1) There is not a linear relationship when converting to methadone from oral morphine. The higher the daily morphine-equivalent dose the more potent methadone is, and 2) conversion to methadone is more of a process than a calculation. In general, the starting methadone dose should not exceed 30 to 40 mg/day, even in patients on high doses of other opioids. Patient response to methadone needs to be monitored closely throughout the process of the conversion. There are several proposed ratios for converting from oral morphine to oral methadone (Ayonrinde 2000; Mercadente 2001; Ripamonti 1998). The estimated total daily methadone dose should then be divided to reflect the intended dosing schedule (eg, divide by 3 and administer every 8 hours). Patients who have not taken an opioid for 1 to 2 weeks should be considered opioid naive (Chou 2014).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Manufacturer's labeling:</b> Dosing in the prescribing information may not reflect current clinical practice. Discontinue all other around-the-clock opioids when methadone therapy is initiated; fatalities have occurred in opioid-tolerant patients during conversion to methadone. Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient's daily methadone requirement and provide breakthrough pain relief with rescue medication (eg, IR opioid) than to overestimate requirements. Patient response to methadone needs to be monitored closely throughout the process of the conversion. For patients on a single opioid, sum the current total daily dose of oral opioid, convert it to a morphine-equivalent dose according to conversion factor for that specific opioid, then multiply the morphine equivalent dose by the corresponding percentage to calculate the approximate oral methadone daily dose. Divide total daily methadone dose by intended dosing schedule (ie, divide by 3 for administration every 8 hours). Round down, if necessary, to the nearest strength available. For patients on a regimen of more than one opioid, calculate the approximate oral methadone dose for each opioid and sum the totals to obtain the approximate total methadone daily dose, and divide the total daily methadone dose by the intended dosing schedule (ie, divide by 3 for administration every 8 hours). For patients on a regimen of fixed-ratio opioid/nonopioid analgesic medications, only the opioid component of these medications should be used in the conversion. <b>Note:</b> Conversion factors listed below are only for the conversion from another opioid analgesic to methadone and cannot be used to convert from methadone to another opioid (doing so may lead to fatal overdose due to overestimation of the new opioid). This does not provide equianalgesic doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Critically ill patients in the ICU (analgesia and sedation) (alternative agent) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used to slow development of tolerance when escalation with other opioids is required or to help wean prolonged continuous opioid infusions. Unpredictable pharmacokinetics/pharmacodynamics in opioid-naive patients. Monitor adverse effects (eg, QTc) and drug-drug interactions (Al-Qadheeb 2012; Elefritz 2016; SCCM [Barr 2013]; Wanzuita 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 to 40 mg every 6 to 12 hours (SCCM [Barr 2013]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2.5 to 10 mg every 8 to 12 hours (SCCM [Barr 2013]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>When used to wean prolonged continuous opioid infusions, titrate no more than every 3 to 5 days and wean continuous opioid infusion to off as tolerated; once continuous opioid infusion is weaned off, methadone can be tapered down by 10% to 25% every 2 to 3 days; discontinue methadone once daily doses of 10 to 15 mg are reached (Elefritz 2016).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d55b3bb-0aaf-4b8c-bd73-27aac1fd99f2">Opioid use disorder, maintenance treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder, maintenance treatment: Note: </b>Diskets can be administered only in 10 mg increments; may not be appropriate product for initial dosing or dose reductions. In patients with pain, temporarily increasing the dose or dosing frequency (eg, divide total daily dose over 3 to 4 times per day) may maximize the analgesic properties for pain management (ASAM 2020). IV route is for use only in patients unable to take oral medication (such as during hospitalization). For IV dosing, convert patient's oral methadone dose to an equivalent parenteral dose using the conversions provided in "Pain, chronic."</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients with no or low tolerance at initiation (eg, absence of opioids ≥5 days, do not take opioids daily, use of weaker opioids [eg, codeine]): <b>Oral:</b> 2.5 to 10 mg (as a single dose) (ASAM 2020; SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients engaging in problem drinking, those with lower levels of opioid tolerance or individuals with medical conditions that may cause hypoxia, hypercapnia or cardiac arrhythmias (eg, asthma, chronic obstructive pulmonary disease, cor pulmonale, electrolyte abnormalities, family history of cardiac arrhythmias, dizziness or fainting or sudden death, kyphoscoliosis, obesity, QTc prolongation, sleep apnea): <b>Oral:</b> 10 to 20 mg (as a single dose) (SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with no signs of sedation or intoxication but with symptoms of withdrawal: <b>Oral:</b> 20 to 30 mg (as a single dose); maximum initial dose: 30 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Regardless of initial dose, observe patients for over-sedation and withdrawal symptoms for 2 to 4 hours after initial dose (ASAM 2020; SAMHSA 2021); an additional 5 to 10 mg orally may be provided if withdrawal symptoms have not been suppressed or if symptoms reappear after 2 to 4 hours; total daily dose on the first day should not exceed 40 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance:</b>
<b>Oral: </b>Titrate cautiously to a dosage which prevents opioid withdrawal symptoms for 24 hours, prevents craving, attenuates euphoric effect of self-administered opioids, and tolerance to sedative effects of methadone. Some experts recommend increasing by no more than 10 mg every 5 days. Slower titrations such as 5 mg every week should be considered in patients with no or low tolerance at initiation (eg, absence of opioids ≥5 days, do not take opioids daily, use of weaker opioids [eg, codeine]) (ASAM 2020; SAMHSA 2021). If a patient experiences sedation 2 to 4 hours after their last dose and craving or withdrawal prior to the next dose, consider dividing the daily dose into twice daily dosing. If patient experiences relief from withdrawal 4 to 12 hours after their last dose, maintain this dose for a few days so methadone can reach steady state (SAMHSA 2021). Levels will accumulate over the first few days; deaths have occurred in early treatment due to cumulative effects. Usual range: 60 to 120 mg/day (ASAM 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Missed dose: In patients who miss &gt;4 doses, consider restarting at the initial dose or decrease the next dose substantially and gradually re-titrate (SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Switching therapies:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Methadone to buprenorphine: </i>Taper the methadone dose gradually to 30 to 40 mg and remain on that dose for ≥7 days. Discontinue methadone at least 24 hours before the first dose of buprenorphine; the patient should be in mild withdrawal before starting buprenorphine, which is typically 24 to 48 hours after the last dose of methadone. Initiating buprenorphine at lower doses (eg, 2 mg) decreases risk of precipitated methadone withdrawal (ASAM 2020; SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Methadone to naltrexone:</i> Taper the methadone dose gradually and discontinue. Wait 7 to 14 days before initiating treatment with naltrexone (ASAM 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Naltrexone to methadone:</i> Begin methadone ~1 day following last dose of oral naltrexone and ~28 days following last dose of IM naltrexone (ASAM 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Discontinuation of therapy: When discontinuing methadone for long-term treatment of opioid use disorder, reduce dose gradually by 5% to 10% every 1 to 2 weeks. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both. In some cases, patients who experience cravings at low doses (20 to 40 mg) may choose to switch to buprenorphine to complete discontinuation or to naltrexone for maintenance treatment (SAMHSA 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0fc38b43-a826-4d6f-9fe8-e04158e50f4c">Opioid withdrawal, short-term medically supervised</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid withdrawal, short-term medically supervised: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Maintenance treatment with methadone is associated with better outcomes than short-term medically supervised withdrawal. Reserve medically supervised withdrawal for patients who do not wish to undergo maintenance treatment or who will be transitioning to maintenance treatment with naltrexone (SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b>
<b>Oral: </b>Titrate to ~40 mg/day in divided doses to achieve stabilization.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance:</b>
<b>Oral: </b>May continue 40 mg/day dose for 2 to 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Discontinuation of therapy: After 2 to 3 days at a stable dose, gradually decrease the dose on a daily basis or at 2-day intervals. Keep dose at a level sufficient to keep withdrawal symptoms at a tolerable level. Hospitalized patients may tolerate a total daily dose decrease of 20%; ambulatory patients may require a slower reduction.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion from oral opioids to oral methadone:</i></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Oral Morphine to Oral Methadone Conversion Factors</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Total daily baseline oral morphine dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Estimated daily oral methadone requirement as percent of total daily morphine dose</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">&lt;100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">20% to 30%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">100 to 300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">10% to 20%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">300 to 600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">8% to 12%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">600 to 1,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">5% to 10%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">&gt;1,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">&lt;5%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion from oral morphine to parenteral methadone: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Switching a patient from another chronically administered opioid to methadone requires caution because of the uncertainty of dose conversion ratios and incomplete cross-tolerance. Deaths have occurred in opioid-tolerant patients during conversion to methadone.</p>
<p style="text-indent:-2em;margin-left:4em;">Conversion ratios in many commonly used equianalgesic dosing tables do not apply for repeated methadone dosing. Although the onset and duration of analgesic action and the analgesic potency of methadone and morphine are similar with single-dose administration, methadone's potency increases over time with repeated dosing. Furthermore, the conversion ratio between methadone and other opiates varies dramatically, depending on baseline opiate (morphine equivalent) use.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Oral Morphine to IV Methadone Conversion for Chronic Administration</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Total daily baseline oral morphine dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Estimated daily IV methadone as percent of total daily oral morphine dose<sup>a</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>The total daily methadone dose derived from the previous table may then be divided to reflect the intended dosing schedule (ie, for administration every 8 hours, divide total daily methadone dose by 3).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">10% to 15%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 to 300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">5% to 10%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 to 600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">4% to 6%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 to 1,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">3% to 5%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;1,000 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">&lt;3%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion from parenteral morphine to parenteral methadone:</i></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Parenteral Morphine to IV Methadone Conversion for Chronic Administration<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Total daily baseline parenteral morphine dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Estimated daily parenteral methadone requirement as percent of total daily morphine dose<sup>b</sup></b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Derived from previous table assuming a 3:1 oral:parenteral morphine ratio.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>The total daily methadone dose derived from the previous table may then be divided to reflect the intended dosing schedule (ie, for administration every 8 hours, divide total daily methadone dose by 3).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">10 to 30 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40% to 66%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">30 to 50 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27% to 66%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">50 to 100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22% to 50%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">100 to 200 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15% to 34%</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">200 to 500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10% to 20%</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Equianalgesic methadone dosing varies among patients and within a single patient, depending on baseline morphine (or other opioid) dose. The conversion tables have been included in order to illustrate this concept and to provide a safe starting point for opioid conversion. Methadone dosing should not be based solely on these tables. Methadone conversion and dose-titration methods should always be individualized to account for the patient's prior opioid exposure, general medical condition, concomitant medication, and anticipated breakthrough medication use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion from IV methadone to oral methadone:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose: IV to Oral ratio: Although the 1:2 (IV methadone to oral methadone) ratio is recommended by the manufacturer, consider using the more conservative ratio of 1:1.3 (IV methadone to oral methadone), especially in patients at risk of somnolence and/or respiratory depression (Liu 2021; manufacturer’s labeling). Example of 1:1.3 ratio (IV to oral): 8 mg of IV methadone equals ~10 mg of oral methadone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Conversion from oral methadone to IV methadone:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose: Oral to IV ratio: No direct conversion or equivalency exists. Alternatives to conversion to IV methadone include conversion to a different oral or IV opioid (at an equivalent dose) or consider converting oral methadone to IV methadone using a conservative conversion ratio of 2:1 (oral methadone:IV methadone); monitor closely for adequate pain relief and adverse effects (McPherson 2019). Example: 10 mg of oral methadone equals 5 mg of IV methadone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> When reducing the dose, discontinuing, or tapering long-term opioid therapy, the dose should be gradually tapered. An optimal tapering schedule has not been established. Individualize tapering based on discussions with patient to minimize withdrawal, while considering patient-specific goals and concerns and the opioid’s pharmacokinetics. Proposed initial schedules range from slow (eg, 10% reduction per week or 10% reduction per month depending on duration of long-term therapy) to rapid (eg, 25% to 50% reduction every few days) (CDC 2015; CDC [Dowell 2022]). Slower tapers may be appropriate after long-term use (eg, &gt;1 year), whereas more rapid tapers may be appropriate in patients experiencing severe adverse effects. During tapering, patients may be at an increased risk of overdose if they return to their original (or higher) opioid dose or use illicit opioids, due to rapid loss of tolerance; consider prescribing naloxone. Monitor carefully for signs/symptoms of withdrawal. If the patient displays withdrawal symptoms, consider slowing the taper schedule; alterations may include increasing the interval between dose reductions, decreasing amount of daily dose reduction, pausing the taper and restarting when the patient is ready, and/or coadministration of an alpha-2 agonist (eg, clonidine) to blunt autonomic withdrawal symptoms and other adjunctive agents to treat GI symptoms and muscle spasms, as needed. Continue to offer nonopioid analgesics as needed for pain management during the taper (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991580"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Methadone concentrations are not substantially altered in patients with kidney impairment (Kreek 1980); however, patients with advanced chronic kidney disease are more likely to have multiple comorbidities, a prolonged QT interval, and take sodium bicarbonate supplements (alkalinization of the urine can prolong methadone excretion [Nilsson 1982]) and other concomitant therapies increasing the risk of drug-drug interactions; close monitoring by a pain or substance use disorder specialist is warranted in these patients (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Parenteral administration is for use only in patients unable to take oral medication (such as during hospitalization).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: <b>Oral, parenteral:</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (Aronoff 2007; Kreek 1980; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;10 to &lt;30 mL/minute: Initial: No dosage adjustment necessary; use with caution and consider more gradual dose titration (Aronoff 2007; Kreek 1980; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤10 mL/minute: Initial: Administer 50% to 75% of the usual indication-specific dose; use with caution; titrate gradually (Aronoff 2007; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly removed by hemodialysis (~2% to 15% removal) (Furlan 1999; Opdal 2015; Perlman 2013):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, parenteral:</b> Initial: Administer 50% to 75% of the usual indication-specific dose; titrate gradually. Supplemental post-hemodialysis dosing is not necessary (Furlan 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly removed (Kreek 1980):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, parenteral:</b> Initial: Administer 50% to 75% of the usual indication-specific dose; titrate gradually (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, CNS and respiratory depression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, parenteral:</b> Use of alternative agents may be preferred, particularly in methadone-naive patients, since use of methadone in patients on CRRT has not been evaluated; however, if use of methadone is deemed necessary, a dose reduction (eg, administer 50% to 75% of the usual indication-specific dose) should be considered in patients initiating and established on methadone therapy, based on patient's clinical condition and comorbidities. Titrate based on tolerance and response (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT </b>
<b>(eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, CNS and respiratory depression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, parenteral:</b> Use of alternative agents may be preferred, particularly in methadone-naive patients, since use of methadone in patients on PIRRT has not been evaluated; however, if use of methadone is deemed necessary, a dose reduction (eg, administer 50% to 75% of the usual indication-specific dose) should be considered in patients initiating and established on methadone therapy, based on patient's clinical condition and comorbidities Titrate based on tolerance and response (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988761"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, undergoes hepatic metabolism and systemic exposure may be increased after repeated dosing. Initiate at lower doses and titrate slowly; monitor closely for respiratory and CNS depression.</p></div>
<div class="block arsc drugH1Div" id="F58766224"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced constipation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opioid-induced <b>constipation</b> (OIC) is the most common subtype of opioid-induced bowel dysfunction, which is a broader term that encompasses additional GI opioid-induced adverse reactions including nausea, vomiting, and gastroesophageal reflux. Symptoms of OIC may include decreased frequency of bowel movements, straining to pass bowel movements, a sense of incomplete evacuation, and/or hard stools (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30340754','lexi-content-ref-30788113','lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30340754','lexi-content-ref-30788113','lexi-content-ref-30778756'])">Ref</a></span>). Tolerance does not develop to OIC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28034973','lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28034973','lexi-content-ref-30778756'])">Ref</a></span>). Symptoms are reversible after discontinuation of the opioid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28034973','lexi-content-ref-11755892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28034973','lexi-content-ref-11755892'])">Ref</a></span>). Reported incidence of OIC with methadone ranges from 17% to over 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054032','lexi-content-ref-27603712','lexi-content-ref-34182372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054032','lexi-content-ref-27603712','lexi-content-ref-34182372'])">Ref</a></span>). OIC is the most common reason for discontinuation reported by patients and may often result in a longer hospital stay and increased overall healthcare costs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20727708','lexi-content-ref-11755892','lexi-content-ref-25278772','lexi-content-ref-15221581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20727708','lexi-content-ref-11755892','lexi-content-ref-25278772','lexi-content-ref-15221581'])">Ref</a></span>). Opioid dose or route of administration does not appear to alter risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20100280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20100280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; mu-opioid receptor stimulation in the GI tract results in delayed gastric emptying, decreased peristalsis, decreased water and chloride secretion into the intestinal lumen, and slowed bowel motility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30788113','lexi-content-ref-15153834','lexi-content-ref-11755892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30788113','lexi-content-ref-15153834','lexi-content-ref-11755892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; constipation has been reported within the first several weeks of methadone maintenance therapy initiation and after longer periods of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gray.1','lexi-content-ref-29054032','lexi-content-ref-35719767','lexi-content-ref-26567239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gray.1','lexi-content-ref-29054032','lexi-content-ref-35719767','lexi-content-ref-26567239'])">Ref</a></span>). However, OIC is defined based on a 7-day period of change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30778756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other medications that cause constipation</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054032','lexi-content-ref-27603712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054032','lexi-content-ref-27603712'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methadone is associated with serious, life-threatening, or fatal opioid-induced <b>respiratory depression</b> (OIRD). Effects include hypoventilation, hypoxia, hypercapnia, and respiratory acidosis, as well as reduced ventilatory responses to hypoxia and hypercapnia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35965031','lexi-content-ref-18456641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35965031','lexi-content-ref-18456641'])">Ref</a></span>). Peak respiratory depression from methadone occurs later and lasts longer than the peak analgesic effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20087676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20087676'])">Ref</a></span>). Respiratory depression may be reversible upon drug discontinuation (with opioid antagonist therapy in appropriate patients).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; stimulation of mu-opioid receptors in the brainstem leads to suppression of the respiratory control network and depression of normal hypoxic and hypercapnic ventilatory responses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30915997','lexi-content-ref-35965031','lexi-content-ref-18456641','lexi-content-ref-35189729','lexi-content-ref-18489633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30915997','lexi-content-ref-35965031','lexi-content-ref-18456641','lexi-content-ref-35189729','lexi-content-ref-18489633'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; OIRD develops within 12 to 14 hours after oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30778756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Improper dosing and/or titration during initiation, following a dose increase, or conversion to methadone</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid naïve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20087676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20087676'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid misuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28646524']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28646524'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute overdose</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of benzodiazepines, alcohol, or other CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552274'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Postoperative patients with comorbid cardiac or respiratory disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552274','lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552274','lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Deitch.1','lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Deitch.1','lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sleep disorder (eg, obstructive sleep apnea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552274','lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552274','lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic pulmonary disease (eg, COPD, cor pulmonale, hypoxia, hypercapnia)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cachexia</p>
<p style="text-indent:-2em;margin-left:6em;">• Debilitation</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abruptly stopping or reducing opioid use in patients with physical dependence on opioids can result in opioid-induced withdrawal (OIW) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668','lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668','lexi-content-ref-30701615'])">Ref</a></span>). Physical symptoms may include nausea, vomiting, diarrhea, abdominal cramps, tachycardia, chills, muscle aches, bone pain, agitation, anxiety, and insomnia. Cases of withdrawal psychosis have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26991984','lexi-content-ref-34286498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26991984','lexi-content-ref-34286498'])">Ref</a></span>). Symptoms of withdrawal from methadone may be milder than symptoms from withdrawal of short-acting opioids but may last longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Withdrawal; opioids bind to mu-opioid receptors on neurons in the locus coeruleus (LC) of the brainstem, causing decreased norepinephrine (NE) release. Upon abrupt discontinuation, the absence of opioid stimulation causes LC hyperactivity, excessive NE release, and subsequent autonomic hyperactivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; symptoms peak at 72 to 96 hours after the last methadone dose and may persist for 2 weeks or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged exposure to opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation or rapid tapering</p>
<p style="text-indent:-2em;margin-left:6em;">• Initiation of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics in patients currently or recently taking methadone can cause precipitated opioid withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36704210','lexi-content-ref-35623179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36704210','lexi-content-ref-35623179'])">Ref</a></span>). Precipitated withdrawal is similar to OIW, but with a faster onset, and is associated with a decrease in opioid use disorder treatment retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22514846','lexi-content-ref-34954746','lexi-content-ref-33818748','lexi-content-ref-20682186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22514846','lexi-content-ref-34954746','lexi-content-ref-33818748','lexi-content-ref-20682186'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methadone is associated with life-threatening <b>prolonged QT interval on ECG</b>, <b>torsades de pointes</b>, and sudden cardiac death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18187075','lexi-content-ref-35658484','lexi-content-ref-20177760','lexi-content-ref-25815024','lexi-content-ref-35658478','lexi-content-ref-12820821','lexi-content-ref-22026519','lexi-content-ref-15918160','lexi-content-ref-29849428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18187075','lexi-content-ref-35658484','lexi-content-ref-20177760','lexi-content-ref-25815024','lexi-content-ref-35658478','lexi-content-ref-12820821','lexi-content-ref-22026519','lexi-content-ref-15918160','lexi-content-ref-29849428'])">Ref</a></span>). QT prolongation to &gt;500 msec is estimated to occur in 2% to 10% of patients treated with methadone and is reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22026519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22026519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; however, QT prolongation has also been reported at lower doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30071529','lexi-content-ref-12820821','lexi-content-ref-22168435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30071529','lexi-content-ref-12820821','lexi-content-ref-22168435'])">Ref</a></span>). Inhibition of the human ether-à-go-go–related gene (hERG) channel and rapid component of the delayed rectifier potassium current (<i>I</i>
<sub>Kr</sub>) leads to prolonged cardiac repolarization, prolonged action potential, and increased QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35658478','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35658478','lexi-content-ref-32929996'])">Ref</a></span>), thereby increasing the risk of torsades de pointes and sudden cardiac death. Additional prolongation of the cardiac action potential through inhibition of the inward rectifier potassium current (<i>I</i>
<sub>K1</sub>) has also been proposed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35658478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35658478'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; initial detection of QT prolongation has been reported within 1 month of methadone initiation to beyond 12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12820821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12820821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher daily methadone doses (eg, &gt;120 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV &gt; oral administration if IV formulation contains the preservative chlorobutanol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14527710','lexi-content-ref-19153406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14527710','lexi-content-ref-19153406'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• QTc &gt;450 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-24685458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-24685458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired hepatic drug metabolism (eg, hepatic dysfunction or drug-drug interactions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20185054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20185054'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• CYP450 2B6 slow metabolizer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12405865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12405865'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypokalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20087676','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20087676','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypomagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20087676','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20087676','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications that prolong the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20087676','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20087676','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20185054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20185054'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of cardiac conduction abnormalities</p>
<p style="text-indent:-2em;margin-left:6em;">• Structural heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20185054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20185054'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22026519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22026519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20087676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20087676'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F193961"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bigeminy, bradycardia, cardiac arrhythmia, cardiomyopathy, edema, extrasystoles, flushing, heart failure, hypotension, palpitations, phlebitis, shock, syncope, tachycardia, ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, hemorrhagic urticaria, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, antidiuretic effect, decreased libido, decreased plasma testosterone, hypokalemia, hypomagnesemia, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, biliary tract spasm, glossitis, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Asthenospermia, decreased ejaculate volume, defective spermatogenesis (morphologic abnormalities), hypogonadism, male genital disease (reduced seminal vesicle secretions), prostatic disease (reduced prostate secretions), urinary hesitancy, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (IV), pain at injection site (IV), swelling at injection site (IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, asthenia, confusion, disorientation, dizziness, drug abuse, drug dependence, dysphoria, euphoria, hallucination, headache, insomnia, neonatal withdrawal, sedated state, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Amyotrophy, bone fracture, osteoporosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Nystagmus disorder, strabismus, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema, respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG abnormality (including inversion T wave on ECG and prolonged QT interval on ECG) (Krantz 2003), torsades de pointes (Traficante 2017), ventricular tachycardia (Tam 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperprolactinemia (transient increase with chronic use) (Molitch 2008), hypoglycemia (Flory 2016; Malboosbaf 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (Kandhi 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Allodynia (opioid-induced hyperalgesia) (FDA Safety Communication 2023), neurotoxicity (including choreiform movements and encephalopathy) (Gasimova 2022)</p></div>
<div class="block coi drugH1Div" id="F193978"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis) to methadone or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma (in the absence of resuscitative equipment or in an unmonitored setting); GI obstruction, including paralytic ileus (known or suspected).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Contraindications may vary per product labeling; refer also to product labels: Diarrhea associated with pseudomembranous colitis or caused by poisoning until toxic material has been eliminated from the GI tract; concurrent use or use within 14 days of an MAOI; hypercarbia; obstructive airway; mild, intermittent, or short duration pain that can be managed with other pain medications; management of acute pain; patients naive to opioids; diseases/conditions affecting bowel transit (known or suspected); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); status asthmaticus; cor pulmonale; acute alcohol intoxication; delirium tremens; convulsive disorders; severe CNS depression; increased cerebrospinal or intracranial pressure; head injury; breastfeeding, pregnancy and during labor/delivery.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F193958"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental opioid overdose: Patients who had been treated with methadone may respond to lower opioid doses than previously used. This could result in potentially life-threatening opioid intoxication. Patients should be aware that they may be more sensitive to lower doses of opioids after treatment with methadone is discontinued, after a missed dose, or near the end of the dosing interval.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperalgesia: Opioid-induced hyperalgesia (OIH) has occurred with short-term and prolonged use of opioid analgesics. Symptoms may include increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily nonpainful stimuli; symptoms may be suggestive of OIH if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior. Consider decreasing the current opioid dose or opioid rotation in patients who experience OIH.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. Avoid use in patients with obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to mood disorders and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression/coma: Avoid use in patients with impaired consciousness or coma, because these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delirium tremens: Use with caution in patients with delirium tremens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to potential increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use with caution in patients who are morbidly obese.</p>
<p style="text-indent:-2em;margin-left:4em;">• Opioid use disorder: When used for detoxification and maintenance of opioid use disorder, methadone should be administered in accordance with the treatment standards cited in 42 CFR Section 8, including limitations on unsupervised administration. Regulatory exceptions to the general requirements for certification to provide opioid agonist treatment include inpatient treatment of other conditions and emergency period (not &gt;3 days) while definitive substance use disorder treatment is being sought.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use with caution in patients with toxic psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with seizure disorders; may cause or exacerbate seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and CNS depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment), resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and CNS depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]). Consider the use of alternative nonopioid analgesics in these patients when possible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine (FD&amp;C yellow no. 5), which may cause allergic reactions in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: Use with caution in patients with a history of substance use disorder; potential for drug dependency exists. Other factors associated with increased risk for misuse include concomitant depression or other mental health conditions, higher opioid dosages, or taking other CNS depressants. Consider offering naloxone prescriptions in patients with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (≥50 morphine milligram equivalents [MME]/day orally), concomitant benzodiazepine use, and patients at risk for returning to a high dose after losing tolerance (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Outpatient setting: Opioids should <b>not</b> be used as first-line therapy for acute (&lt;1 month duration), subacute (1 to 3 month duration), or chronic pain (&gt;3 month duration [outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-based opioid use disorder treatment]). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, nonsteroidal anti-inflammatory drugs, acetaminophen, certain antiseizure medications, antidepressants) as appropriate for the specific condition. If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks and realistic benefits of opioid therapy should be discussed with the patient. Therapy should be initiated at the lowest effective dosage using IR opioids (instead of ER/long-acting opioids). For the treatment of acute pain, therapy should only be given for the expected duration of pain severe enough to require opioids and prescribed as needed (not scheduled). For the treatment of subacute and chronic pain, realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Risk to patients increases with higher opioid dosages. Dosages ≥50 MME/day are likely to not have increased benefit to pain relief or function relative to overall risk to patients; before increasing dosage to ≥50 MME/day, readdress pain and reassess evidence of individual benefits and risks (CDC [Dowell 2022]). In patients taking methadone who have acute pain refractory to other treatments and require additional opioid-based analgesia, adding short-acting full agonist opioids may be considered; however, the dose required is anticipated to be higher than the typical dose in opioid-naive patients (ASAM 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: There is no maximum recommended duration for maintenance treatment of opioid use disorder with methadone; patients may continue treatment indefinitely as long as treatment is beneficial. Increased duration of therapy is associated with better treatment outcomes. Advise patients who are not yet stable of the potential to relapse to illicit drug use following discontinuation of methadone medication-based opioid use disorder treatment (SAMHSA 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Incomplete cross-tolerance: Use caution in converting patients from other opioids to methadone. Follow appropriate conversion schedules. Patients tolerant to other mu opioid agonists may not be tolerant to methadone and at risk for severe respiratory depression when converted to methadone.</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.</p>
<p style="text-indent:-2em;margin-left:4em;">• Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: In patients undergoing elective surgery (excluding caesarean section), consider discontinuation of methadone the day before or day of surgery. In patients unable to abruptly discontinue methadone prior to surgery, full opioid agonists may be added to the methadone to maintain proper analgesia. If opioid therapy is required as part of analgesia, patients should be continuously monitored in an anesthesia care setting by persons not involved in in the conduct of the surgical or diagnostic procedure. The decision whether to discontinue methadone prior to elective surgery should be made in consultation with the surgeon and anesthesiologist. If discontinued, methadone can be resumed postoperatively when there is no longer a need for full opioid agonist therapy; in general, presurgery daily doses may be resume if held for &lt;2 to 3 days (ASAM 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Switching formulations: Use caution with close monitoring if switching from one methadone formulation to another in patients with opioid use disorder; decreased efficacy, including withdrawal symptoms, has been reported; dose adjustments may be necessary (Health Canada 2020).</p></div>
<div class="block foc drugH1Div" id="F193970"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methadone HCl Intensol: 10 mg/mL (30 mL) [unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methadose: 10 mg/mL (1000 mL) [contains fd&amp;c red #40 (allura red ac dye), methylparaben, propylene glycol, propylparaben; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methadose Sugar-Free: 10 mg/mL (1000 mL) [dye free, sugar free; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (30 mL, 1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (5 mL, 500 mL); 10 mg/5 mL (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methadose: 40 mg [scored; contains fd&amp;c yellow #5 (tartrazine)aluminum lake, fd&amp;c yellow #6 (sunset yellow), fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg</p></div>
<div class="block geq drugH1Div" id="F193954"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5989406"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Methadone HCl Intensol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Methadone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.10 - $0.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Methadose Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Methadose Sugar-Free Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methadone HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $25.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methadone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.08 - $0.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $0.14 - $0.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Methadone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.30 - $0.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Methadose Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methadone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.07 - $0.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.15 - $0.70</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867494"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol: 10 mg/mL (100 mL) [contains propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol-D: 10 mg/mL (100 mL) [contains propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methadose: 10 mg/mL (1000 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol: 5 mg/5 mL (250 mL) [contains methylparaben, polyethylene glycol (macrogol), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol-D: 1 mg/mL (100 mL, 250 mL) [contains methylparaben, polyethylene glycol (macrogol), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol: 1 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol: 25 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol: 5 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metadol: 10 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p></div>
<div class="block csi drugH1Div" id="F194038"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block accres drugH1Div" id="F11234073"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">When used for treatment of opioid use disorder: May only be dispensed in accordance to guidelines established by the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT). Regulations regarding methadone use may vary by state and/or country. Obtain advice from appropriate regulatory agencies and/or consult with pain management/palliative care specialists.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Regulatory Exceptions to the General Requirement to Provide Opioid Agonist Treatment (per manufacturer's labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">1. During inpatient care, when the patient was admitted for any condition other than concurrent opioid use disorder, to facilitate the treatment of the primary admitting diagnosis.</p>
<p style="text-indent:-2em;margin-left:4em;">2. During an emergency period of no longer than 3 days while definitive care for the substance use disorder is being sought in an appropriately licensed facility.</p></div>
<div class="block admp drugH1Div" id="F52613275"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution (1 mg/mL): Administer using an accurate measuring device (calibrated oral syringe).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets for oral suspension: Disperse tablet in ~120 mL (4 oz) of water, orange juice, or other acidic fruit juice; if insoluble excipients remain and do not entirely dissolve, add a small amount of liquid to cup and administer remaining mixture. Do not chew or swallow tablet before dispersing.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: May be administered IV or SUBQ; rate of IV administration is not defined. The absorption of SUBQ appears to be unpredictable; local tissue reactions may occur.</p></div>
<div class="block adm drugH1Div" id="F193975"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Tablets for oral suspension: For oral administration only; do not inject (contains insoluble excipients). Disperse tablet in ~120 mL of water, orange juice, or other acidic fruit beverage prior to administration; if insoluble excipients remain and do not entirely dissolve, add a small amount of liquid to cup and administer remaining mixture. Do not chew or swallow tablet before dispersing in liquid.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> Administer IM, SUBQ, or IV; rate of IV administration not defined. Absorption of SUBQ and IM appears to be unpredictable. Local tissue reactions may occur.</p></div>
<div class="block sts drugH1Div" id="F193990"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F). Protect from light. Store vials in carton until ready for use.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral concentrate: Store at 20°C to 25°C (68°F to 77°F); protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution, tablet, tablet for oral suspension: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Metadol [Canadian product], Metadol-D [Canadian product]: Store at 15°C to 30°C (59°F to 86°F). Protect tablets from light. Protect oral concentrate and oral solution from light and freezing. After dilution of oral concentrate in compatible diluent, may store at 2°C to 8°C (35.6°F to 46.4°F) for 7 or 14 days (refer to manufacturer labeling for specific recommendations)</p></div>
<div class="block meg drugH1Div" id="F14624980"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Dolophine tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F006134s050lbl.pdf%23page%3D36&amp;token=2%2FndgSvGjJHFT9HK%2FSTk%2BeiCUQpdQwKumbYMd9qMhfLeAVkDu0tPd%2BiVsKdx%2B6r7dg35LpZgcZ%2FnNJwngCH4P9RZOYIVrQiat%2F0sux%2Fg4NL%2BS6kPAuJrfEHA8ObGMSsY&amp;TOPIC_ID=12590" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/006134s050lbl.pdf#page=36</a></p></div>
<div class="block usep drugH1Div" id="F53567762"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Management of pain severe enough to require an opioid analgesic and for which alternative treatment options are inadequate (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (Oral solution, concentrate [Intensol], regular tablets: FDA approved in adults); short-term medically supervised opioid withdrawal and maintenance treatment of opioid use disorder, in conjunction with appropriate social and medical services (Oral solution, concentrate [Intensol, Methadose], dispersible tablets: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for the treatment of neonatal abstinence syndrome and iatrogenic opioid dependency and for perioperative analgesia.</p></div>
<div class="block mst drugH1Div" id="F194046"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Methadone may be confused with dexmethylphenidate, ketorolac, memantine, Mephyton, methylphenidate, Metadate CD, Metadate ER, metOLazone, morphine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F194032"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F193963"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abacavir: Methadone may diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Amisulpride (Oral).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aromatase Inhibitors: May increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Methadone. Methadone may decrease the serum concentration of Atazanavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: May enhance the CNS depressant effect of Methadone. Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: May enhance the CNS depressant effect of Methadone. Cannabidiol may increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of Methadone. Ceritinib may increase the serum concentration of Methadone. Management: Consider alternatives to this combination. Methadone dose reduction may be necessary when used with ceritinib. With any concurrent use, monitor closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Citalopram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clarithromycin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of CloZAPine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2B6 Inducers (Moderate): May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Methadone. Management: If coadministration with moderate CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Methadone. Management: If coadministration with strong CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of Methadone. Dabrafenib may decrease the serum concentration of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and reduced methadone efficacy. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DAPTOmycin: Methadone may decrease the serum concentration of DAPTOmycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Methadone. More specifically, the combination of Darunavir and Ritonavir may decrease Methadone serum concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Dasatinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Methadone may decrease the serum concentration of Didanosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin-Containing Products: May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of Methadone. DroPERidol may enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives. If combined, dose reductions are recommended. Monitor for additive toxicities such as QTc interval prolongation, ventricular arrhythmias, and CNS depression. Patients with additional risk factors are at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Methadone. Encorafenib may decrease the serum concentration of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and decreased methadone effects/withdrawal. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Escitalopram.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias (including TdP) with a continuous overnight ECG when fingolimod is combined with QT prolonging drugs. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flecainide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Flupentixol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: Methadone may enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Methadone.  Management: Monitor for increased methadone effects/toxicities if combined with fluvoxamine. Also monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May enhance the QTc-prolonging effect of Methadone. Fostemsavir may increase the serum concentration of Methadone. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. If use is necessary, monitor for QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the CNS depressant effect of Methadone. Haloperidol may enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation or those taking IV haloperidol may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Alfa): May increase the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May enhance the QTc-prolonging effect of Methadone. Itraconazole may increase the serum concentration of Methadone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Methadone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levofloxacin-Containing Products (Systemic): May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May enhance the QTc-prolonging effect of Methadone. Lopinavir may decrease the serum concentration of Methadone. More specifically, the combination of Lopinavir and Ritonavir may decrease Methadone serum concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lubiprostone: Methadone may diminish the therapeutic effect of Lubiprostone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Methadone may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to methadone or mequitazine when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Methadone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moxifloxacin (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Moxifloxacin (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: Opioid Agonists may enhance the adverse/toxic effect of Nalfurafine. Opioid Agonists may diminish the therapeutic effect of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4).  Management: If concomitant use of opioid agonists that are metabolized by CYP3A4 and nefazodone is necessary, consider dose reduction of the opioid until stable drug effects are achieved. Monitor for increased opioid effects and serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of OLANZapine.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Osimertinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pacritinib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May enhance the CNS depressant effect of Methadone. PHENobarbital may decrease the serum concentration of Methadone. Management: Avoid concomitant use of methadone and phenobarbital when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pilsicainide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pilsicainide.  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Pimozide.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the CNS depressant effect of Methadone. Primidone may decrease the serum concentration of Methadone. Management: Avoid concomitant use of methadone and primidone when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Probucol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the CNS depressant effect of Methadone. Methadone may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, sedation, and respiratory depression. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): Methadone may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Methadone may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for increased methadone toxicities (eg, respiratory depression, QTc interval prolongation). Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Methadone. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Methadone. Management: Consider alternatives to this combination. Methadone dose reductions may be necessary. With any concurrent use, monitor closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of QUEtiapine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the metabolism of Methadone. Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Agents (Highest Risk) may enhance the CNS depressant effect of RisperiDONE. QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May enhance the QTc-prolonging effect of Methadone. Saquinavir may decrease the serum concentration of Methadone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and opioid withdrawal symptoms. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Methadone may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparfloxacin: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Sparfloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stavudine: Methadone may decrease the serum concentration of Stavudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of SUNItinib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Methadone. More specifically, the combination of Tipranavir and Ritonavir may decrease Methadone serum concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Vemurafenib.  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May enhance the QTc-prolonging effect of Methadone. Voriconazole may increase the serum concentration of Methadone. Management: Consider alternatives to this combination. Methadone dose reduction may be necessary when used with voriconazole. With any concurrent use, monitor closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Methadone may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F193992"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit/grapefruit juice may increase levels of methadone. Management: Monitor for increased effects/toxicity with concomitant use.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308177"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pregnancy testing is recommended prior to initiating therapy for opioid use disorders (ASAM 2020; SAMHSA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic opioid use may cause hypogonadism and hyperprolactinemia which may decrease fertility in patients of reproductive potential. Menstrual cycle disorders (including amenorrhea), erectile dysfunction, and impotence have been reported. The incidence of hypogonadism may be increased with the use of opioids in high doses or long-acting opioid formulations. It is not known if the effects on fertility are reversible. Monitor patients on long-term therapy (de Vries 2020; Gadelha 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Consider family planning, contraception, and the effects on fertility prior to prescribing opioids for chronic pain to patients who could become pregnant (ACOG 2017; CDC [Dowell 2022]). Contraception should also be discussed with patients undergoing treatment for opioid use disorders (ASAM 2020).</p></div>
<div class="block pri drugH1Div" id="F193980"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methadone crosses the placenta and can be detected in cord blood, amniotic fluid, and newborn urine.</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of major malformation has not been observed in the majority of available studies. Data related to specific malformations or other adverse events such as decreased fetal growth, premature birth, and sudden infant death syndrome are inconsistent. Children exposed to methadone in utero may have mild persistent deficits in performance on psychometric and behavioral tests; visual abnormalities may also occur. Pregnant patients in methadone treatment programs are reported to have improved prenatal care and fetal outcomes compared to pregnant patients using illicit drugs. Untreated opioid issue disorder is also associated with adverse pregnancy outcomes including low birth weight, preterm birth, and fetal death.</p>
<p style="text-indent:0em;margin-top:2em;">Neonatal abstinence syndrome (NAS)/neonatal opioid withdrawal syndrome (NOWS) may occur following prolonged in utero exposure to opioids (CDC [Dowell 2022]). NAS/NOWS may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. Presentation of symptoms varies by opioid characteristics (eg, immediate release, sustained release), time of last dose prior to delivery, drug metabolism (maternal, placental, and infant), net placental transfer, as well as other factors (AAP [Hudak 2012]; AAP [Patrick 2020]). Clinical signs characteristic of withdrawal following in utero opioid exposure include excessive crying or easily irritable, fragmented sleep (&lt;2 to 3 hours after feeding), tremors, increased muscle tone, or GI dysfunction (hyperphagia, poor feeding, feeding intolerance, watery or loose stools) (Jilani 2022). NAS/NOWS occurs following chronic opioid exposure and would not be expected following the use of opioids at delivery (AAP [Patrick 2020]). The risk of NAS/NOWS is not greater when methadone is used as part of a treatment program compared to the risk following illicit opioid use (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Opioid agonist pharmacotherapy is recommended for pregnant patients with an opioid use disorder (ACOG 2017; ASAM 2020; SAMHSA 2021). Treatment should begin as early in pregnancy as possible (ASAM 2020; CDC [Dowell 2022]) and may continue when pregnancy occurs during treatment (ASAM 2020). Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of methadone may be altered as pregnancy progresses (clearance may be increased and half-life may be decreased). Dose adjustments or splitting of a once-daily dose may be required in some patients (ASAM 2020; SAMHSA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Maintenance doses of methadone for the treatment of opioid use disorder will not provide adequate pain relief during labor. Patients receiving methadone for the treatment of opioid use disorder should be maintained on their daily dose of methadone in addition to receiving the same pain management options during labor and delivery as opioid-naive patients. Opioid agonist-antagonists should be avoided for the treatment of labor pain in patients maintained on methadone due to the risk of precipitating acute withdrawal. Use of a multimodal approach to pain relief which can maximize nonopioid interventions is recommended. Monitor for maternal oversedation and somnolence (ACOG 2017; Krans 2019; SAMHSA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor infants of mothers on long-term/chronic opioid therapy for symptoms of withdrawal. Symptom onset reflects the half-life of the opioid used. Monitor infants for at least 5 to 7 days following exposure to methadone (AAP [Patrick 2020]; CDC [Dowell 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Opioids are not preferred for the treatment of chronic noncancer pain during pregnancy; consider strategies to minimize or avoid opioid use. Advise pregnant patients requiring long-term opioid use of the risk of NAS/NOWS and provide appropriate treatment for the neonate after delivery. NAS/NOWS is an expected and treatable condition following chronic opioid use during pregnancy and should not be the only reason to avoid treating pain with an opioid in pregnant patients (ACOG 2017; CDC [Dowell 2022]). Do not abruptly discontinue opioids during pregnancy; taper prior to discontinuation when appropriate, considering the risks to the pregnant patient and fetus if maternal withdrawal occurs (CDC [Dowell 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53567761"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory rate and oxygen saturation, blood pressure and heart rate, and mental status, pain relief (if used for analgesia), abstinence scoring system (if used for neonatal abstinence syndrome), withdrawal assessment score (if used for iatrogenic withdrawal); ECG for monitoring QTc interval prior to initiating therapy, after starting dose and with each titration in patients with risk factors for prolonged QT interval, a history of cardiac conduction abnormalities and those taking medications affecting cardiac conduction; level of sedation; signs of misuse, abuse, and substance use disorder.</p></div>
<div class="block pha drugH1Div" id="F193957"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression. Methadone has also been shown to have N-methyl-D-aspartate (NMDA) receptor antagonism.</p></div>
<div class="block phk drugH1Div" id="F193977"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: Analgesic: 0.5 to 1 hour; Parenteral: 10 to 20 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Parenteral: 1 to 2 hours; Oral: Continuous dosing: 3 to 5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Analgesia: Oral: 4 to 8 hours (single-dose studies); duration of analgesia may increase to 8 to 12 hours with repeated dosing due to the slow release from the liver and other tissues (Alford 2006; Fishman 2002; Mercadante 1996; Toombs 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Craving: 24 to 36 hours (ASAM 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Lipophilic</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates PNA: &lt;72 hours: 2.53 L/kg (Wiles 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: 7.1 ± 2.5 L/kg (Berde 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 1 to 8 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85% to 90%, primarily to alpha-1 acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; N-demethylation primarily via CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6 to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 36% to 100%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: 19.2 ± 13.6 hours (range: 3.8 to 62 hours) (Berde 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 8 to 59 hours; may be prolonged with alkaline pH. Auto-induction of metabolism may shorten the half-life during first month of treatment in some patients (Eap 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 7.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;10% as unchanged drug); increased with urine pH &lt;6; <b>Note:</b> Methadone may persist in the liver and other tissues; slow release from tissues may prolong the pharmacologic effect despite low serum concentrations.</p></div>
<div class="block phksp drugH1Div" id="F51159465"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Methadone is metabolized by hepatic pathways; therefore, there is a risk of drug accumulation after multiple dosing in patients with hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F193982"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Gobbidona | Metacalmans | Metadona clorhidrato mallinckrodt</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Heptadon</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Physeptone</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mephenon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Metadon | Mytedom</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ketalgin | Ketalgine | Methadon streuli</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amidona</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Methadone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Metadona | Metadona clorhidrato | Methadose</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Methaddict</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Metadon dak | Methadone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Metasedin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dolmed | Metadon abcur</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Methadone | Physeptone</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Methadone | Physeptone</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Heptanon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Depridol | Metadon-ep</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Adolan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">R meth</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eptadone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Methapain</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mephenon | Methaddict</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amidone | Amidone liquid | Rubidexol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aseptone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Methadon HCL | Methadon HCl Apotex | Methadon hcl aurobindo | Methadon hcl teva | Methadon HCl TioFarma | Methadon Regenboog | Symoron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Metadon | Metadon abcur | Metadon Nycomed | Methadon Alternova</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Methadone | Methadone bnm | Methadone HCL | Pallidone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Metadol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Methadon streuli</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Methadose</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Genofin | Methadose</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Metadon 2care4 | Metadon abcur | Metadon orion | Metadon Recip</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Physeptone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Heptanon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Methadone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Metafin ic | Methadict | Methadol | Methadone zn</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Metadon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30915997">
<a name="30915997"></a>Algera MH, Kamp J, van der Schrier R, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. <i>Br J Anaesth</i>. 2019;122(6):e168-e179. doi:10.1016/j.bja.2018.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30915997/pubmed" id="30915997" target="_blank">30915997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22872749">
<a name="22872749"></a>Al-Qadheeb NS, Roberts RJ, Griffin R, Garpestad E, Ruthazer R, Devlin JW. Impact of enteral methadone on the ability to wean off continuously infused opioids in critically ill, mechanically ventilated adults: a case-control study. <i>Ann Pharmacother.</i> 2012;46(9):1160-1166. doi: 10.1345/aph.1R132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22872749/pubmed" id="22872749" target="_blank">22872749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16418412">
<a name="16418412"></a>Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. <i>Ann Intern Med</i>. 2006;144(2):127-134. doi:10.7326/0003-4819-144-2-200601170-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/16418412/pubmed" id="16418412" target="_blank">16418412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric Analgesia and Anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742676">
<a name="28742676"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Obstetrics. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. <i>Obstet Gynecol</i>. 2017;130(2):e81-e94. doi:10.1097/AOG.0000000000002235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/28742676/pubmed" id="28742676" target="_blank">28742676</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP); Section on Breastfeeding. Breastfeeding and the use of human milk. <i>Pediatrics</i>. 2012;129(3):e827-e841. doi:10.1542/peds.2011-3552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22371471/pubmed" id="22371471" target="_blank">22371471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511106">
<a name="32511106"></a>American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. <i>J Addict Med</i>. 2020;14(2S)(suppl 1):1‐91. doi:10.1097/ADM.0000000000000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/32511106/pubmed" id="32511106" target="_blank">32511106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8306694">
<a name="8306694"></a>Anand KJ, Arnold JH. Opioid tolerance and dependence in infants and children. <i>Crit Care Med.</i> 1994;22(2):334-342.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/8306694/pubmed" id="8306694" target="_blank">8306694</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. </i>5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11194738">
<a name="11194738"></a>Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. <i>Med J Aust</i>. 2000;173(10):536-540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/11194738/pubmed" id="11194738" target="_blank">11194738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med.</i> 2013;41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30071529">
<a name="30071529"></a>Behzadi M, Joukar S, Beik A. Opioids and cardiac arrhythmia: a literature teview. <i>Med Princ Pract</i>. 2018;27(5):401-414. doi:10.1159/000492616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30071529/pubmed" id="30071529" target="_blank">30071529</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Berde CB, Sethna NF, Holsman RS, Reidy P, Gondek EJ. Pharmacokinetics of methadone in children and adolescents in the perioperative period. <i>Anesthesiology</i>. 1987;67(3A):A519. http://anesthesiology.pubs.asahq.org/pdfaccess.ashx?url=/data/journals/jasa/931395. Accessed May 3, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32199668">
<a name="32199668"></a>Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. <i>Drug Alcohol Depend</i>. 2020;211:107932. doi:10.1016/j.drugalcdep.2020.107932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/32199668/pubmed" id="32199668" target="_blank">32199668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25357093">
<a name="25357093"></a>Brown MS, Hayes MJ, Thornton LM. Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. <i>J Perinatol</i>. 2015;35(4):278-283. doi:10.1038/jp.2014.194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/25357093/pubmed" id="25357093" target="_blank">25357093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22514846">
<a name="22514846"></a>Center for Substance Abuse Treatment (CSAT). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. Report No: (SMA) 04-3939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22514846/pubmed" id="22514846" target="_blank">22514846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Common elements in guidelines for prescribing opioids for chronic pain. <a href="https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf" target="_blank">https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf</a>. Published 2015. Accessed June 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685458">
<a name="24685458"></a>Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. <i>J Pain</i>. 2014;15(4):321-337. doi: 10.1016/j.jpain.2014.01.494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/24685458/pubmed" id="24685458" target="_blank">24685458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18187075">
<a name="18187075"></a>Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone.<i> Am J Med</i>. 2008;121(1):66-71. doi:10.1016/j.amjmed.2007.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/18187075/pubmed" id="18187075" target="_blank">18187075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26991984">
<a name="26991984"></a>Cobo J, Ramos MM, Peláez T, García G, Marsal F. Psychosis related to methadone withdrawal. <i>Acta Neuropsychiatr</i>. 2006;18(1):50-51. doi:10.1111/j.0924-2708.2006.00109.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26991984/pubmed" id="26991984" target="_blank">26991984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34954746">
<a name="34954746"></a>Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low dose initiation of buprenorphine: a narrative review and practical approach. <i>J Addict Med</i>. 2022; 16(4):399-406. doi:10.1097/ADM.0000000000000945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/34954746/pubmed" id="34954746" target="_blank">34954746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15378662">
<a name="15378662"></a>Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. <i>Hum Psychopharmacol</i>. 2004;19(8):565-576. doi:10.1002/hup.630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15378662/pubmed" id="15378662" target="_blank">15378662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30340754">
<a name="30340754"></a>Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. <i>Gastroenterology</i>. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30340754/pubmed" id="30340754" target="_blank">30340754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29913015">
<a name="29913015"></a>Davis JM, Shenberger J, Terrin N, et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. <i>JAMA Pediatr</i>. 2018;172(8):741-748. doi:10.1001/jamapediatrics.2018.1307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/29913015/pubmed" id="29913015" target="_blank">29913015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511863">
<a name="31511863"></a>de Vries F, Bruin M, Lobatto DJ, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab.</i> 2020;105(3):1020-1029. doi:10.1210/clinem/dgz022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/31511863/pubmed" id="31511863" target="_blank">31511863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15504625">
<a name="15504625"></a>Dean M. Opioids in renal failure and dialysis patients. <i>J Pain Symptom Manage</i>. 2004;28(5):497-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15504625/pubmed" id="15504625" target="_blank">15504625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33818748">
<a name="33818748"></a>De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. <i>Clin Drug Investig</i>. 2021;41(5):425-436. doi:10.1007/s40261-021-01032-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/33818748/pubmed" id="33818748" target="_blank">33818748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Deitch.1">
<a name="Deitch.1"></a>Deitch K, Domingo G, Kowalski M, Chudnosky C, Dominici P. 318 the 1 plus 1 hydromorphone pain protocol has similar efficacy as physician discretion analgesia and is less safe in older adults: a randomized trial. 2-15. Available at: https://doi.org/10.1080/14659890412331318912. Last accessed November 14, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/Deitch.1/pubmed" id="Deitch.1" target="_blank">Deitch.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Diskets (methadone) [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; December 2023.</div>
</li>
<li>
<div class="reference">
                  Dolophine (methadone) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12659598">
<a name="12659598"></a>Dominguez KD, Lomako DM, Katz RW, Kelly HW. Opioid withdrawal in critically ill neonates. <i>Ann Pharmacother</i>. 2003;37(4):473-477. doi:10.1345/aph.1C324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/12659598/pubmed" id="12659598" target="_blank">12659598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327391">
<a name="36327391"></a>Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. <i>MMWR Recomm Rep</i>. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/36327391/pubmed" id="36327391" target="_blank">36327391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20185054">
<a name="20185054"></a>Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>J Am Coll Cardiol</i>. 2010;55(9):934-947. doi:10.1016/j.jacc.2010.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/20185054/pubmed" id="20185054" target="_blank">20185054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12405865">
<a name="12405865"></a>Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. <i>Clin Pharmacokinet.</i> 2002;41(14):1153-1193. doi:10.2165/00003088-200241140-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/12405865/pubmed" id="12405865" target="_blank">12405865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35658484">
<a name="35658484"></a>Eckhardt LL. Arrhythmogenesis and prolonged repolarization from synthetic opioids: finally sorted? <i>J Am Heart Assoc</i>. 2022;11(11):e025778. doi:10.1161/JAHA.122.025778<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35658484/pubmed" id="35658484" target="_blank">35658484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27288616">
<a name="27288616"></a>Elefritz JL, Murphy CV, Papadimos TJ, Lyaker MR. Methadone analgesia in the critically ill. <i>J Crit Care</i>. 2016;34:84-88. doi: 10.1016/j.jcrc.2016.03.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/27288616/pubmed" id="27288616" target="_blank">27288616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30788113">
<a name="30788113"></a>Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O'Brien T, Morlion B, Tack J. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. <i>United European Gastroenterol J</i>. 2019;7(1):7-20. doi:10.1177/2050640618818305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30788113/pubmed" id="30788113" target="_blank">30788113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15099239">
<a name="15099239"></a>Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. <i>Pain Med</i>. 2002;3(4):339-348. doi:10.1046/j.1526-4637.2002.02047.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15099239/pubmed" id="15099239" target="_blank">15099239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342726">
<a name="26342726"></a>Flory JH, Wiesenthal AC, Thaler HT, et al. Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain. <i>J Pain Symptom Manage</i>. 2016;51(1):79-87.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26342726/pubmed" id="26342726" target="_blank">26342726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28646524">
<a name="28646524"></a>Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. <i>Addiction</i>. 2018;113(1):59-66. doi:10.1111/add.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/28646524/pubmed" id="28646524" target="_blank">28646524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22093817">
<a name="22093817"></a>Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. <i>Pain</i>. 2012;153(1):142-148. doi: 10.1016/j.pain.2011.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22093817/pubmed" id="22093817" target="_blank">22093817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10052536">
<a name="10052536"></a>Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM. Methadone is poorly removed by haemodialysis. <i>Nephrol Dial Transplant.</i> 1999;14(1):254-255. doi:10.1093/ndt/14.1.254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/10052536/pubmed" id="10052536" target="_blank">10052536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35066756">
<a name="35066756"></a>Gadelha MR, Karavitaki N, Fudin J, Bettinger JJ, Raff H, Ben-Shlomo A. Opioids and pituitary function: expert opinion. <i>Pituitary</i>. 2022;25(1):52-63. doi:10.1007/s11102-021-01202-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35066756/pubmed" id="35066756" target="_blank">35066756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24379233">
<a name="24379233"></a>Galinkin J, Koh JL; Committee on Drugs; Section On Anesthesiology and Pain Medicine; American Academy of Pediatrics. Recognition and management of iatrogenically induced opioid dependence and withdrawal in children. <i>Pediatrics</i>. 2014;133(1):152-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/24379233/pubmed" id="24379233" target="_blank">24379233</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy</i>. New York: Springer; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gray.1">
<a name="Gray.1"></a>Gray D, Spence D. The prevalence of constipation in patients receiving methadone maintenance treatment for opioid dependency. <i>Journal of Substance Use.</i> 2009:10:6:397-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/Gray.1/pubmed" id="Gray.1" target="_blank">Gray.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30552274">
<a name="30552274"></a>Gupta K, Nagappa M, Prasad A, Abrahamyan L, Wong J, Weingarten TN, Chung F. Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses. <i>BMJ Open</i>. 2018;8(12):e024086. doi:10.1136/bmjopen-2018-024086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30552274/pubmed" id="30552274" target="_blank">30552274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054032">
<a name="29054032"></a>Haber PS, Elsayed M, Espinoza D, Lintzeris N, Veillard AS, Hallinan R. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. <i>Drug Alcohol Depend</i>. 2017;181:132-139. doi:10.1016/j.drugalcdep.2017.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/29054032/pubmed" id="29054032" target="_blank">29054032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26703873">
<a name="26703873"></a>Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome. <i>J Pediatr</i>. 2016;170:39-44.e1. doi:10.1016/j.jpeds.2015.11.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26703873/pubmed" id="26703873" target="_blank">26703873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26477866">
<a name="26477866"></a>Hall ES, Meinzen-Derr J, Wexelblatt SL. Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome. <i>J Pediatr</i>. 2015;167(6):1221-5.e1. doi:10.1016/j.jpeds.2015.09.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26477866/pubmed" id="26477866" target="_blank">26477866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20177760">
<a name="20177760"></a>Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. <i>J Interv Card Electrophysiol</i>. 2010;28(1):19-22. doi:10.1007/s10840-009-9465-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/20177760/pubmed" id="20177760" target="_blank">20177760</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Health Canada. Methadone treatment of opioid dependence and potential risk of lack of effect when switching between different products. <a href="https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73547a-eng.php" target="_blank">https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73547a-eng.php</a>. Published July 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20727708">
<a name="20727708"></a>Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. <i>J Pain Symptom Manage</i>. 2010;40(5):696-703. doi:10.1016/j.jpainsymman.2010.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/20727708/pubmed" id="20727708" target="_blank">20727708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC, Committee On Drugs, et al. Neonatal drug withdrawal. <i>Pediatrics.</i> 2012;129(2):e540-e560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33675100">
<a name="33675100"></a>Isaac L, van den Hoogen NJ, Habib S, Trang T. Maternal and iatrogenic neonatal opioid withdrawal syndrome: Differences and similarities in recognition, management, and consequences. <i>J Neurosci Res</i>. 2022;100(1):373-395. doi:10.1002/jnr.24811<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/33675100/pubmed" id="33675100" target="_blank">33675100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34942181">
<a name="34942181"></a>Jilani SM, Jones HE, Grossman M, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. <i>J Pediatr.</i> 2022;243:33-39.e1. doi:10.1016/j.jpeds.2021.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/34942181/pubmed" id="34942181" target="_blank">34942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35719767">
<a name="35719767"></a>Kandhi S, Chinta S, Urena Neme AP, Victoria Guerrero M, Rodriguez Guerra MA. Acute hydronephrosis secondary to methadone-induced constipation. <i>Cureus</i>. 2022 May;14(5):e25090. doi:10.7759/cureus.25090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35719767/pubmed" id="35719767" target="_blank">35719767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25815024">
<a name="25815024"></a>Khalesi S, Shemirani H, Dehghani-Tafti F. Methadone induced torsades de pointes and ventricular fibrillation: a case review. <i>ARYA Atheroscler</i>. 2014;10(6):339-342.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/25815024/pubmed" id="25815024" target="_blank">25815024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925318">
<a name="32925318"></a>Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. <i>Anesth Analg</i>. 2020 Oct;131(4):1012-1024. doi:10.1213/ANE.0000000000004788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/32925318/pubmed" id="32925318" target="_blank">32925318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35658478">
<a name="35658478"></a>Klein MG, Krantz MJ, Fatima N, et al. Methadone blockade of cardiac inward rectifier K+ current augments membrane instability and amplifies U waves on surface ECGs: a translational study. <i>J Am Heart Assoc</i>. 2022;11(11):e023482. doi:10.1161/JAHA.121.023482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35658478/pubmed" id="35658478" target="_blank">35658478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14527710">
<a name="14527710"></a>Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. <i>Pain</i>. 2003;105(3):499-506. doi:10.1016/S0304-3959(03)00205-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/14527710/pubmed" id="14527710" target="_blank">14527710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30701615">
<a name="30701615"></a>Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. <i>Am J Addict</i>. 2019;28(2):55-62. doi:10.1111/ajad.12862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30701615/pubmed" id="30701615" target="_blank">30701615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12724485">
<a name="12724485"></a>Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. <i>N Engl J Med</i>. 2003 May;348(18):1786-1795. doi:10.1056/NEJMra020617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/12724485/pubmed" id="12724485" target="_blank">12724485</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Krans EE, Campopiano M, Cleveland LM, et al. National partnership for maternal safety: Consensus bundle on obstetric care for women with opioid use disorder. <i>Obstet Gynecol</i>. 2019;134(2):365-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/31306323/pubmed" id="31306323" target="_blank">31306323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12820821">
<a name="12820821"></a>Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. <i>Pharmacotherapy</i>. 2003;23(6):802-805. doi:10.1592/phco.23.6.802.32186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/12820821/pubmed" id="12820821" target="_blank">12820821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19153406">
<a name="19153406"></a>Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. <i>Ann Intern Med</i>. 2009;150(6):387-395. doi:0.7326/0003-4819-150-6-200903170-00103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/19153406/pubmed" id="19153406" target="_blank">19153406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6986247">
<a name="6986247"></a>Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. <i>Drug Alcohol Depend.</i> 1980;5(3):197-205. doi:10.1016/0376-8716(80)90180-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/6986247/pubmed" id="6986247" target="_blank">6986247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28430046">
<a name="28430046"></a>Lai A, Philpot P, Boucher J, Meyer A. An outpatient methadone weaning program by a neonatal intensive care unit for neonatal abstinence syndrome. <i>Popul Health Manag</i>. 2017;20(5):397-401. doi:10.1089/pop.2016.0192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/28430046/pubmed" id="28430046" target="_blank">28430046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16202968">
<a name="16202968"></a>Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Hagadorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. <i>Adv Neonatal Care</i>. 2005;5(5):265-272. doi:10.1016/j.adnc.2005.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/16202968/pubmed" id="16202968" target="_blank">16202968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33872344">
<a name="33872344"></a>Liu J, Smith KE, Riker RR, et al. Methadone bioavailability and dose conversion implications with intravenous and enteral administration: a scoping review. <i>Am J Health Syst Pharm</i>. 2021;78(15):1395-1401. doi:10.1093/ajhp/zxab166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/33872344/pubmed" id="33872344" target="_blank">33872344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34286498">
<a name="34286498"></a>Lozano-López MT, Gamonal-Limcaoco S, Casado-Espada N, et al. Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review. <i>Eur Rev Med Pharmacol Sci</i>. 2021;25(13):4554-4562. doi:10.26355/eurrev_202107_26248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/34286498/pubmed" id="34286498" target="_blank">34286498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27603712">
<a name="27603712"></a>Lugoboni F, Mirijello A, Zamboni L, et al. High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. <i>Expert Opin Pharmacother</i>. 2016;17(16):2135-2141. doi:10.1080/14656566.2016.1232391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/27603712/pubmed" id="27603712" target="_blank">27603712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26513313">
<a name="26513313"></a>Madadi P, Kelly LE, Ross CJ, Kepron C, Edwards JN, Koren G. Forensic investigation of methadone concentrations in deceased breastfed infants. <i>J Forensic Sci</i>. 2016;61(2):576-580. doi: 10.1111/1556-4029.12972.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26513313/pubmed" id="26513313" target="_blank">26513313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28609177">
<a name="28609177"></a>Madden K, Bruera E. Very-low-dose methadone to treat refractory neuropathic pain in children with cancer. <i>J Palliat Med</i>. 2017;20(11):1280-1283. doi:10.1089/jpm.2017.0098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/28609177/pubmed" id="28609177" target="_blank">28609177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31195079">
<a name="31195079"></a>Madden K, Jo E, Williams JL, Liu D, Bruera E. Corrected QT interval prolongation in pediatric and young adult patients on methadone for cancer-related pain. <i>J Pain Symptom Manage</i>. 2019a;58(4):678-684. doi:10.1016/j.jpainsymman.2019.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/31195079/pubmed" id="31195079" target="_blank">31195079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30447383">
<a name="30447383"></a>Madden K, Liu D, Bruera E. Attitudes, beliefs, and practices of pediatric palliative care physicians regarding the use of methadone in children with advanced cancer. <i>J Pain Symptom Manage</i>. 2019b;57(2):260-265. doi:10.1016/j.jpainsymman.2018.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30447383/pubmed" id="30447383" target="_blank">30447383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36201002">
<a name="36201002"></a>Malboosbaf R, Hatami N, Maghsoomi Z. Methadone-induced hypoglycemia: a case report. <i>J Diabetes Investig</i>. 2023;14(1):145-146. doi:10.1111/jdi.13919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/36201002/pubmed" id="36201002" target="_blank">36201002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM Clinical Protocol #28: Peripartum analgesia and anesthesia for the breastfeeding mother.<i> Breastfeed Med</i>. 2018;13(3):164-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22026519">
<a name="22026519"></a>Martin JA, Campbell A, Killip T, et al. QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. <i>J Addict Dis</i>. 2011;30(4):283-306. doi:10.1080/10550887.2011.610710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22026519/pubmed" id="22026519" target="_blank">22026519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15153834">
<a name="15153834"></a>McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. <i>Cancer Control</i>. 2004;11(3 Suppl):3-9. doi:10.1177/10732748040110S302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15153834/pubmed" id="15153834" target="_blank">15153834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30578934">
<a name="30578934"></a>McPherson ML, Walker KA, Davis MP, et al. Safe and appropriate use of methadone in hospice and palliative care: expert consensus white paper. <i>J Pain Symptom Manage</i>. 2019;57(3):635-645.e4. doi:10.1016/j.jpainsymman.2018.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30578934/pubmed" id="30578934" target="_blank">30578934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35921640">
<a name="35921640"></a>Meek JY, Noble L; Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk. <i>Pediatrics</i>. 2022;150(1):e2022057988. doi:10.1542/peds.2022-057988.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35921640/pubmed" id="35921640" target="_blank">35921640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879376">
<a name="8879376"></a>Mercadante S, Sapio M, Serretta R, Caligara M. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. <i>Ann Oncol.</i> 1996;7(6):613-617. doi:10.1093/oxfordjournals.annonc.a010679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/8879376/pubmed" id="8879376" target="_blank">8879376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Metadol-D.1">
<a name="Metadol-D.1"></a>Metadol-D (methadone) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; June 2023.</div>
</li>
<li>
<div class="reference">
                  Metadol (methadone) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Methadone.1">
<a name="Methadone.1"></a>Methadone Hydrochloride Intensol [prescribing information]. Birkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; March 2022.</div>
</li>
<li>
<div class="reference">
                  Methadone Hydrochloride oral concentrate [prescribing information]. Largo, FL: VistaPharm Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Methadone Hydrochloride oral solution [prescribing information]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc; July 2020.</div>
</li>
<li>
<div class="reference">
                  Methadone Hydrochloride oral solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Camber.1">
<a name="Camber.1"></a>Methadone Hydrochloride tablets [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Methadone Hydrochloride tablets [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; October 2023.</div>
</li>
<li>
<div class="reference">
                  Methadone injection [prescribing information]. Morgantown, WV: Mylan Institutional LLC; December 2023.</div>
</li>
<li>
<div class="reference">
                  Methadose dispersible tablet (methadone) [prescribing information]. Webster Groves, MO: SpecGx LLC; February 2021.</div>
</li>
<li>
<div class="reference">
                  Methadose oral concentrate and Methadose sugar-free oral concentrate (methadone hydrochloride) [prescribing information]. Webster Groves, MO: Mallinckrodt Inc; December 2023.</div>
</li>
<li>
<div class="reference">
                  Methadose (methadone) [product monograph]. Pointe-Claire, Quebec, Canada: Mallinckrodt Canada ULC; February 2019.</div>
</li>
<li>
<div class="reference">
                  Methadose (methadone) tablet for oral suspension [prescribing information]. Webster Groves, MO: SpecGx LLC; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20087676">
<a name="20087676"></a>Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: risk factors in pain and addicted populations. <i>J Gen Intern Med</i>. 2010;25(4):305-309. doi:10.1007/s11606-009-1225-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/20087676/pubmed" id="20087676" target="_blank">20087676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18404390">
<a name="18404390"></a>Molitch ME. Drugs and prolactin. <i>Pituitary</i>. 2008;11(2):209-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/18404390/pubmed" id="18404390" target="_blank">18404390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35965031">
<a name="35965031"></a>Montandon G. The pathophysiology of opioid-induced respiratory depression. <i>Handb Clin Neurol</i>. 2022;188:339-355. doi:10.1016/B978-0-323-91534-2.00003-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35965031/pubmed" id="35965031" target="_blank">35965031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29954057">
<a name="29954057"></a>Mott C, Sarpal A, Moss K, Herbert A. Methadone for analgesia in children with life-limiting illness: experience from a tertiary children's health service. <i>Children (Basel)</i>. 2018;5(7):86. doi:10.3390/children5070086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/29954057/pubmed" id="29954057" target="_blank">29954057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28034973">
<a name="28034973"></a>Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. <i>Pain Med</i>. 2017;18(10):1837-1863. doi:10.1093/pm/pnw255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/28034973/pubmed" id="28034973" target="_blank">28034973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6286317">
<a name="6286317"></a>Nilsson MI, Widerlöv E, Meresaar U, Anggård E. Effect of urinary pH on the disposition of methadone in man.<i> Eur J Clin Pharmacol.</i> 1982;22(4):337-342. doi:10.1007/BF00548403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/6286317/pubmed" id="6286317" target="_blank">6286317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25963997">
<a name="25963997"></a>Opdal MS, Arnesen M, Müller LD, et al. Effects of hemodialysis on methadone pharmacokinetics and QTc. <i>Clin Ther.</i> 2015;37(7):1594-1599. doi:10.1016/j.clinthera.2015.04.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/25963997/pubmed" id="25963997" target="_blank">25963997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11755892">
<a name="11755892"></a>Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction.<i> Am J Surg</i>. 2001;182(5A Suppl):11S-18S. doi:10.1016/s0002-9610(01)00782-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/11755892/pubmed" id="11755892" target="_blank">11755892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33106341">
<a name="33106341"></a>Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn; Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. <i>Pediatrics.</i> 2020;146(5):e2020029074. doi:10.1542/peds.2020-029074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/33106341/pubmed" id="33106341" target="_blank">33106341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18456641">
<a name="18456641"></a>Pattinson KT. Opioids and the control of respiration. <i>Br J Anaesth</i>. 2008;100(6):747-758. doi:10.1093/bja/aen094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/18456641/pubmed" id="18456641" target="_blank">18456641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35189729">
<a name="35189729"></a>Pattullo GG. Clinical implications of opioid-induced ventilatory impairment. <i>Anaesth Intensive Care</i>. 2022;50(1-2):52-67. doi:10.1177/0310057X211070292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35189729/pubmed" id="35189729" target="_blank">35189729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15918160">
<a name="15918160"></a>Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. <i>Pharmacoepidemiol Drug Saf</i>. 2005;14(11):747-753. doi:10.1002/pds.1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15918160/pubmed" id="15918160" target="_blank">15918160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23973378">
<a name="23973378"></a>Perlman R, Giladi H, Brecht K, et al. Intradialytic clearance of opioids: methadone versus hydromorphone. <i>Pain</i>. 2013;154(12):2794-2800. doi:10.1016/j.pain.2013.08.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/23973378/pubmed" id="23973378" target="_blank">23973378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25278772">
<a name="25278772"></a>Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. <i>Clin Exp Gastroenterol</i>. 2014;7:345-358. doi:10.2147/CEG.S52097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/25278772/pubmed" id="25278772" target="_blank">25278772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25836677">
<a name="25836677"></a>Reece-Stremtan S, Marinelli KA. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. <i>Breastfeed Med.</i> 2015;10(3):135-41. doi:10.1089/bfm.2015.9992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/25836677/pubmed" id="25836677" target="_blank">25836677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9779694">
<a name="9779694"></a>Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what Is the equianalgesic dose ratio? <i>J Clin Oncol.</i> 1998;16(10):3216-3221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/9779694/pubmed" id="9779694" target="_blank">9779694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30778756">
<a name="30778756"></a>Rossi M, Casale G, Badiali D, et al. Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Support Care Cancer</i>. 2019;27(11):4083-4090. doi:10.1007/s00520-019-04688-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30778756/pubmed" id="30778756" target="_blank">30778756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22168435">
<a name="22168435"></a>Roy AK, McCarthy C, Kiernan G, McGorrian C, Keenan E, Mahon NG, Sweeney B. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. <i>Addiction</i>. 2012;107(6):1132-1139. doi:10.1111/j.1360-0443.2011.03767.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22168435/pubmed" id="22168435" target="_blank">22168435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics.</i> 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33481403">
<a name="33481403"></a>Sadhasivam S, Aruldhas BW, Packiasabapathy S, et al. A novel perioperative multidose methadone-based multimodal analgesic strategy in children achieved safe and low analgesic blood methadone levels enabling opioid-sparing sustained analgesia with minimal adverse effects. <i>Anesth Analg</i>. 2021;133(2):327-337. doi:10.1213/ANE.0000000000005366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/33481403/pubmed" id="33481403" target="_blank">33481403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26567239">
<a name="26567239"></a>Samokhvalov AV, Rehm J. Opioid-induced constipation reversal in response to placebo in a patient with a history of IBS receiving methadone maintenance therapy. <i>BMJ Case Rep</i>. 2015;2015:bcr2015211954. doi:10.1136/bcr-2015-211954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26567239/pubmed" id="26567239" target="_blank">26567239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34182372">
<a name="34182372"></a>Sason A, Adelson M, Schreiber S, Peles E. The prevalence of constipation and its relation to sweet taste preference among patients receiving methadone maintenance treatment. <i>Drug Alcohol Depend</i>. 2021;225:108836. doi:10.1016/j.drugalcdep.2021.108836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/34182372/pubmed" id="34182372" target="_blank">34182372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119438">
<a name="35119438"></a>Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. <i>Pediatr Crit Care Med</i>. 2022;23(2):e74-e110. doi:10.1097/PCC.0000000000002873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35119438/pubmed" id="35119438" target="_blank">35119438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36704210">
<a name="36704210"></a>Spadaro A, Faude S, Perrone J, Thakrar AP, Lowenstein M, Delgado MK, Kilaru AS. Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: a case series. <i>J Am Coll Emerg Physicians Open</i>. 2023;4(1):e12880. doi:10.1002/emp2.12880<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/36704210/pubmed" id="36704210" target="_blank">36704210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35623179">
<a name="35623179"></a>Spadaro A, Long B, Koyfman A, Perrone J. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. <i>Am J Emerg Med</i>. 2022;58:22-26. doi:10.1016/j.ajem.2022.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/35623179/pubmed" id="35623179" target="_blank">35623179</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP21-02-01-002. Substance Abuse and Mental Health Services Administration; 2021. <a href="https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002" target="_blank">https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002</a>. Accessed February 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15221581">
<a name="15221581"></a>Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. <i>Support Care Cancer</i>. 2004;12(9):613-618. doi:10.1007/s00520-004-0649-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15221581/pubmed" id="15221581" target="_blank">15221581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15832538">
<a name="15832538"></a>Toombs JD, Kral LA. Methadone treatment for pain states. <i>Am Fam Physician</i>. 2005;71(7):1353-1358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/15832538/pubmed" id="15832538" target="_blank">15832538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29849428">
<a name="29849428"></a>Traficante DC, Feibish G, Kashani J. Methadone-induced torsades de pointes masquerading as seizures. <i>Clin Pract Cases Emerg Med</i>. 2017;1(1):40-43. doi:10.5811/cpcem.2016.11.32664<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/29849428/pubmed" id="29849428" target="_blank">29849428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20100280">
<a name="20100280"></a>Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. <i>Neurogastroenterol Motil</i>. 2010;22(4):424-430, e96. doi:10.1111/j.1365-2982.2009.01458.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/20100280/pubmed" id="20100280" target="_blank">20100280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ullrich.1">
<a name="Ullrich.1"></a>Ullrich C, Duncan J, Joselow M, Wolfe J. Pediatric palliative care. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 7.</div>
</li>
<li>
<div class="reference">
                  US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain. <a href="https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOpioidsCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOpioidsCPG.pdf</a>. Published May 2022. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA drug safety communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>. Published April 13, 2023. Accessed April 17, 2023.</div>
</li>
<li>
<div class="reference">
                  Van Cleave A, Rhee E, Morrison W. Palliative care in the pediatric intensive care unit. In: Fuhrman BP, Zimmerman JJ, Clark RSB, et al, eds. <i>Fuhrman &amp; Zimmerman's Pediatric Critical Care</i>. 5th ed. Elsevier; 2016:chap. 16.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30805946">
<a name="30805946"></a>van Donge T, Samiee-Zafarghandy S, Pfister M, et al. Methadone dosing strategies in preterm neonates can be simplified. <i>Br J Clin Pharmacol</i>. 2019;85(6):1348-1356. doi:10.1111/bcp.13906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/30805946/pubmed" id="30805946" target="_blank">30805946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31270130">
<a name="31270130"></a>Wachman EM, Minear S, Hirashima M, et al. Standard fixed-schedule methadone taper versus symptom-triggered methadone approach for treatment of neonatal opioid withdrawal syndrome. <i>Hosp Pediatr</i>. 2019;9(8):576-584. doi:10.1542/hpeds.2018-0165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/31270130/pubmed" id="31270130" target="_blank">31270130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22420584">
<a name="22420584"></a>Wanzuita R, Poli-de-Figueiredo LF, Pfuetzenreiter F, Cavalcanti AB, Westphal GA. Replacement of fentanyl infusion by enteral methadone decreases the weaning time from mechanical ventilation: a randomized controlled trial. <i>Crit Care</i>. 2012;16(2):R49. doi: 10.1186/cc11250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/22420584/pubmed" id="22420584" target="_blank">22420584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18489633">
<a name="18489633"></a>Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. <i>Pain Med</i>. 2008;9(4):425-432. doi:10.1111/j.1526-4637.2007.00343.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/18489633/pubmed" id="18489633" target="_blank">18489633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20682186">
<a name="20682186"></a>Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO. Factors associated with complicated buprenorphine inductions. <i>J Subst Abuse Treat</i>. 201l;39(1):51-57. doi:10.1016/j.jsat.2010.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/20682186/pubmed" id="20682186" target="_blank">20682186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26364984">
<a name="26364984"></a>Wiles JR, Isemann B, Mizuno T, et al. Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study. <i>J Pediatr</i>. 2015;167(6):1214-1220.e3. doi: 10.1016/j.jpeds.2015.08.032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/26364984/pubmed" id="26364984" target="_blank">26364984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24948346">
<a name="24948346"></a>Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. <i>J Pediatr</i>. 2014;165(3):440-446. doi:10.1016/j.jpeds.2014.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/24948346/pubmed" id="24948346" target="_blank">24948346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeltzer.2020">
<a name="Zeltzer.2020"></a>Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19301934">
<a name="19301934"></a>Zernikow B, Michel E, Craig F, Anderson BJ. Pediatric palliative care: use of opioids for the management of pain. <i>Paediatr Drugs</i>. 2009;11(2):129-151. doi:10.2165/00148581-200911020-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methadone-pediatric-drug-information/abstract-text/19301934/pubmed" id="19301934" target="_blank">19301934</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12590 Version 525.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
